High Throughput Screening

高通量筛选

• 批准号: 10395534
• 负责人: David L. Roman
• 金额: --
• 依托单位: UNIVERSITY OF IOWA
• 依托单位国家: 美国
• 财政年份: 2000
• 资助国家: 美国
• 起止时间: 2000-07-14 至 2026-03-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10395534
• 关键词: Antisense Oligonucleotides; Biological; Biological Assay; Biological Products; Biological Testing; Biology; Biomedical Research; Cancer Biology; Cancer Center Support Grant; Cell Differentiation process; Cells; Chemicals; Clinical; Comprehensive Cancer Center; Detection; Development; Drug Screening; Ensure; Excretory function; Fluorescence; Fluorescence Resonance Energy Transfer; Genes; Goals; Libraries; Malignant Neoplasms; Mediating; Metabolism; Molecular; Neurites; Outcome; Pathway Analysis; Pathway interactions; Patients; Pharmaceutical Chemistry; Pharmaceutical Preparations; Phenotype; Process; Reader; Research Design; Research Personnel; Resource Sharing; Robotics; Running; Services; Signal Pathway; Small Interfering RNA; Techniques; Technology; Testing; Therapeutic; Therapeutic antibodies; Tissues; Toxic effect; Translating; absorption; cancer therapy; cell motility; confocal imaging; data management; detection platform; drug discovery; druggable target; follow-up; high throughput screening; imaging system; in vitro testing; luminescence; member; new therapeutic target; novel; patient derived xenograft model; personalized cancer therapy; pre-clinical; precision medicine; preclinical development; protein expression; research clinical testing; screening; small molecule; small molecule therapeutics; therapeutic development; trafficking; transcription factor

The High Throughput Screening Core (HTS) supports basic and translational biomedical research by designing, optimizing, and running high throughput assays that deliver potential therapeutics for cancer. This is done by integrating robotics, detection systems, chemical /biologics libraries and data management with expertise in optimizing technologies and outcomes along each step in the process. HTS provides Holden Comprehensive Cancer Center (HCCC) members with scalable early, pre-clinical development of therapeutics, including small molecule therapeutics, antibodies, siRNAs, antisense oligonucleotides and other biologics including patient-derived cell therapeutics. It also supports high throughput screening for studies exploring the biology of cancer. The HTS is equipped to perform high-throughput screening in 96-, 384- and 1536- well formats, with plate reader detection (Perkin-Elmer EnVision) using absorbance, fluorescence and luminescence, including advanced FRET and BRET techniques. HTS can also perform high content screening (HCS, Perkin-Elmer Operetta Confocal Imaging System) to detect and quantify phenotypic changes, i.e., cell differentiation, cell migration, neurite outgrowth, and target trafficking or by fluorescence intensities for target protein expression, transcription factor or signaling pathway analysis.

高通量筛选核心 (HTS) 支持基础和转化生物医学研究 设计、优化和运行高通量检测，为癌症提供潜在的治疗方法。这是 通过将机器人技术、检测系统、化学/生物制品库和数据管理与 优化过程中每个步骤的技术和结果的专业知识。 HTS 提供霍顿 综合癌症中心 (HCCC) 成员拥有可扩展的早期临床前治疗开发， 包括小分子疗法、抗体、siRNA、反义寡核苷酸和其他生物制剂 包括患者来源的细胞疗法。它还支持高通量筛选研究探索 癌症生物学。 HTS 能够在 96、384 和 1536 孔中执行高通量筛选 格式，使用吸光度、荧光和酶标仪检测 (Perkin-Elmer EnVision) 发光，包括先进的 FRET 和 BRET 技术。 HTS 还可以进行高内涵筛选 （HCS，Perkin-Elmer Operetta 共焦成像系统）检测和量化表型变化，即细胞 分化、细胞迁移、神经突生长和靶标运输或通过靶标的荧光强度 蛋白质表达、转录因子或信号通路分析。